Amphastar PharmaceuticalsAMPH -0.40%83 ROC (Joel Greenblatt) % is 12.09% as of Mar. 2026, which is 45% below its 10-year median of 22.05. GuruFocus rates AMPH with a GF Scoreâ„¢ of 83/100 and a GF Valueâ„¢ of $48.79 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 976 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 68.65% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Amphastar Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.09%.
The historical rank and industry rank for Amphastar Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
AMPH'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3.98 Med: 22.05 Max: 56.32
Current: 24.12
During the past 13 years, Amphastar Pharmaceuticals's highest ROC (Joel Greenblatt) % was 56.32%. The lowest was -3.98%. And the median was 22.05%.
AMPH's ROC (Joel Greenblatt) % is ranked better than 68.65% of 976
companies
in the Drug Manufacturers industry
Industry Median: 11.405
vs AMPH: 24.12
Amphastar Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 67.50% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Amphastar Pharmaceuticals ROC (Joel Greenblatt) % Related Terms
Amphastar Pharmaceuticals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Amphastar Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, PCRX, BIOA: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 12.09% mean?
Amphastar Pharmaceuticals (AMPH) has a ROC (Joel Greenblatt) % of 12.09% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Amphastar Pharmaceuticals and its competitors. This is 45% below median its historical median of 22.05. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #306 out of 976 companies in the Drug Manufacturers industry, placing it in the top 31.4%.
Is Amphastar Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Amphastar Pharmaceuticals' current ROC (Joel Greenblatt) % of 12.09% is 45% below median its 10-year median of 22.05. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.41. Amphastar Pharmaceuticals' value of 12.09% is 6% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #306 out of 976 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Scoreâ„¢ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' ROC (Joel Greenblatt) % compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #306 out of 976 companies for ROC (Joel Greenblatt) %. This puts Amphastar Pharmaceuticals in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.41. Amphastar Pharmaceuticals' value of 12.09% is 6% above this benchmark. While the company's 10-year median is 22.05 vs. the industry median of 11.41, Amphastar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 976 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current ROC (Joel Greenblatt) % of 12.09% is 6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current ROC (Joel Greenblatt) % is 12.09%, which is 45% below median its own 10-year median of 22.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $20.10 — trading 58.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 12.09%, which is 45% below median its 10-year median of 22.05 and 6% above the Drug Manufacturers industry median of 11.41. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current ROC (Joel Greenblatt) % is 12.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.10 is trading 58.8% below its estimated GF Value™ of $48.79.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
ROC (Joel Greenblatt) %: 12.09% (45% below median its 10-year median of 22.05)
GF Value™: $48.79 vs. price of $20.10 (58.8% below fair value)
Industry Position: 6% above the Drug Manufacturers median (#306 of 976)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
